83 related articles for article (PubMed ID: 9548532)
1. Extending insulin action in vivo by conjugation to carboxymethyl dextran.
Baudys M; Letourneur D; Liu F; Mix D; Jozefonvicz J; Kim SW
Bioconjug Chem; 1998; 9(2):176-83. PubMed ID: 9548532
[TBL] [Abstract][Full Text] [Related]
2. Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life.
Shahnaz G; Iqbal J; Rahmat D; Perera G; Laffleur F; Rossi D; Bernkop-Schnürch A
J Control Release; 2012 Feb; 157(3):375-82. PubMed ID: 21986100
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
4. Conjugates of insulin with copolymers of N-(2-hydroxypropyl) methacrylamide: effects on smooth muscle cell proliferation.
Chytry V; Letourneur D; Baudys M; Jozefonvicz J
J Biomed Mater Res; 1996 Jun; 31(2):265-72. PubMed ID: 8731216
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran-cysteine conjugate.
Shahnaz G; Perera G; Sakloetsakun D; Rahmat D; Bernkop-Schnürch A
J Control Release; 2010 May; 144(1):32-8. PubMed ID: 20117156
[TBL] [Abstract][Full Text] [Related]
6. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells.
Johansson GS; Arnqvist HJ
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1124-30. PubMed ID: 16803852
[TBL] [Abstract][Full Text] [Related]
7. Reduced immunogenicity of beta-lactoglobulin by conjugation with carboxymethyl dextran.
Hattori M; Nagasawa K; Ohgata K; Sone N; Fukuda A; Matsuda H; Takahashi K
Bioconjug Chem; 2000; 11(1):84-93. PubMed ID: 10639090
[TBL] [Abstract][Full Text] [Related]
8. [Magnetic drug delivery system--adriamycin-carboxymethyl dextran magnetic nanoparticles].
Shi K; Li C; He B
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2000 Mar; 17(1):21-4. PubMed ID: 10879185
[TBL] [Abstract][Full Text] [Related]
9. Polymerized structure and improved physical and biochemical material properties of carboxymethyl dextran-conjugated collagen.
Okada H; Maeda T; Hattori M; Yoshida T; Yoshimura K; Takahashi K
Biosci Biotechnol Biochem; 2008 Jun; 72(6):1438-47. PubMed ID: 18540095
[TBL] [Abstract][Full Text] [Related]
10. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.
Gershonov E; Goldwaser I; Fridkin M; Shechter Y
J Med Chem; 2000 Jun; 43(13):2530-7. PubMed ID: 10891112
[TBL] [Abstract][Full Text] [Related]
11. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs.
Markussen J; Havelund S; Kurtzhals P; Andersen AS; Halstrøm J; Hasselager E; Larsen UD; Ribel U; Schäffer L; Vad K; Jonassen I
Diabetologia; 1996 Mar; 39(3):281-8. PubMed ID: 8721773
[TBL] [Abstract][Full Text] [Related]
12. Solution composition impacts fibronectin immobilization on carboxymethyl-dextran surfaces and INS-1 insulin secretion.
Dubiel EA; Vermette P
Colloids Surf B Biointerfaces; 2012 Jun; 95():266-73. PubMed ID: 22483346
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates.
Lee S; Kim K; Kumar TS; Lee J; Kim SK; Lee DY; Lee YK; Byun Y
Bioconjug Chem; 2005; 16(3):615-20. PubMed ID: 15898729
[TBL] [Abstract][Full Text] [Related]
14. Effect of chemical modification on the pharmacokinetics and biodistribution of carboxymethyl dextran as a drug carrier.
Lee SD; Lim SJ; Kim CK
Drug Deliv; 2002; 9(3):187-93. PubMed ID: 12396736
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action in dogs of slow-acting insulin analog O346.
Ellmerer M; Hamilton-Wessler M; Kim SP; Dea MK; Kirkman E; Perianayagam A; Markussen J; Bergman RN
J Clin Endocrinol Metab; 2003 May; 88(5):2256-62. PubMed ID: 12727983
[TBL] [Abstract][Full Text] [Related]
17. Reduced immunogenicity of beta-lactoglobulin by conjugation with carboxymethyl dextran differing in molecular weight.
Kobayashi K; Hirano A; Ohta A; Yoshida T; Takahashi K; Hattori M
J Agric Food Chem; 2001 Feb; 49(2):823-31. PubMed ID: 11262036
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of monomethoxypoly(ethylene glycol)-insulin conjugates.
Zhang M; Dou H; Yin L; Zhang Y; Zhu S; Yin C
Pharmazie; 2009 Mar; 64(3):190-6. PubMed ID: 19348342
[TBL] [Abstract][Full Text] [Related]
19. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.
Shechter Y; Mironchik M; Rubinraut S; Saul A; Tsubery H; Fridkin M
Bioconjug Chem; 2005; 16(4):913-20. PubMed ID: 16029032
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection.
Sonaje K; Lin KJ; Wey SP; Lin CK; Yeh TH; Nguyen HN; Hsu CW; Yen TC; Juang JH; Sung HW
Biomaterials; 2010 Sep; 31(26):6849-58. PubMed ID: 20619787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
